Breaking Barriers to Motherhood: Successful Conception and Term Delivery in Infertile Women with Hyperprolactinemia - Two Case Reports
Abstract
Purpose: Hyperprolactinemia is a common cause of female infertility, and prolactin-secreting pituitary macroadenomas pose unique challenges for fertility restoration and pregnancy management. Herein, we present two cases of primary infertility due to hyperprolactinemia with distinct etiologies.
Case presentation: Case 1: A 27-year-old woman with two years of amenorrhea and polycystic ovarian morphology did not undergo standard ovulation induction. Her serum prolactin level was 1334 ng/mL, and MRI revealed hemorrhagic pituitary macroadenoma. Dopamine agonist therapy with bromocriptine normalized prolactin to 13.09 ng/mL within six months, restored menses, and resulted in pregnancy complicated by severe preeclampsia, with successful delivery of a viable neonate requiring short-term respiratory support. Case 2: A 29-year-old woman with idiopathic hyperprolactinemia (initial prolactin 59.6 ng/mL) and a dominant right ovarian follicle received bromocriptine, achieving prolactin normalization (16.7 ng/mL) and bilateral follicular development. Adjunctive letrozole and continued dopamine agonist therapy for nine months led to conception and term vaginal delivery, without complications.
Conclusion: These cases highlight that targeted dopamine agonist therapy may effectively normalize prolactin levels, restore ovulation, and achieve healthy term pregnancies in women with hyperprolactinemia, whether macroadenoma- is driven or idiopathic. Early recognition, individualized treatment, and…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.